ESTRO PT 2018

Proton Therapy for Stage II-III Non-Small-Cell Lung Cancer (NSCLC):

3 prospective, multicenter trials in the USA:

❖ Phase III Trial initiated by MGH/MDACC photons versus protons to 74 Gy (completed accrual)

❖ Phase III RTOG trial photons versus protons to 70Gy or lower as per strict OAR constraints (open)

❖ Phase II hypofractionated dose escalation trial 60 Gy at 25 Gy/frct up to 4 Gy/frct– Univ. Florida PTC (open for accrual)